TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25583842

Group type: EXPERIMENTAL
Intervention: Remote cognitive assessment using the Symbol Digit Modalities Test (SDMT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remote cognitive assessment using the Automated Neuropsychological Assessment Metrics (ANAM‐MS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Telehealth testing sessions
Number of subjects: 24
Study: 23884388

Group type: EXPERIMENTAL
Intervention: Iron-biofortified millet meals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular-iron millet meals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-harvest iron-fortified millet meals
Number of subjects: 20
Study: 20873904

Group type: EXPERIMENTAL
Intervention: Capnometry‐assisted respiratory training
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 41
Study: 18442966

Group type: COMPARATOR
Intervention: CPVI group (n = 54)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CPVI + SVCI group (n = 52)
Number of subjects: 106
Study: 16874169

Group type: COMPARATOR
Intervention: Pneumococcal conjugate vaccine (not received)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Pneumococcal infection
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: NTS infections
Number of subjects: 1009
Study: 14571103

Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g twice a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: L-Carnitine
Number of subjects: 120
Study: 10952323

Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 9308260

Group type: EXPERIMENTAL
Intervention: Fluoride released from Rely-a-Bond adhesive
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no fluoride in adhesive)
Number of subjects: 50
Study: 8481936

Group type: EXPERIMENTAL
Intervention: Children with SIADH (n=19)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Children without SIADH (n=12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 23 children measured for Mean arterial pressure (MAP)
Number of subjects: 31
Study: 3555129

Group type: EXPERIMENTAL
Intervention: 10 hours of daily continuous passive motion (CPM) starting on the 2nd postoperative day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed motion using a soft hinged knee brace locked at 10 degrees of flexion, starting on the 7th postoperative day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (motion and delayed motion)
Number of subjects: 18
Study: 31892475

Group type: EXPERIMENTAL
Intervention: Admission protocol for intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Admission by staff midwives and doctors for control group
Number of subjects: 200
Study: 31825939

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 366
Study: 27470931

Group type: EXPERIMENTAL
Intervention: High-Intensity Sprint and Strength Training (HISST) for 13 weeks in young training group (YT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-Intensity Sprint and Strength Training (HISST) for 13 weeks in middle-aged training group (AT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-Intensity Sprint and Strength Training (HISST)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (young control group YC and middle-aged control group AC)
Number of subjects: 36
Study: 26003931

Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO) intervention
Number of subjects: 318

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 318
Study: 24106997

Group type: EXPERIMENTAL
Intervention: Telephone and SMS intervention in addition to usual care
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 180
Study: 21323520

Group type: EXPERIMENTAL
Intervention: Bortezomib and gemcitabine
Number of subjects: 26
Study: 19487625

Group type: EXPERIMENTAL
Intervention: Antipsychotics (clozapine, risperidone, or olanzapine)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pramipexole (a D(3) receptor-preferring agonist)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17554158

Group type: EXPERIMENTAL
Intervention: Rotational junior-sport model combining skills from rugby, cricket, and netball
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified games model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 0
Study: 15531659

Group type: EXPERIMENTAL
Intervention: Fish oil plus antioxidants (2.7 g EPA and DHA/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 62
Study: 11417430

Group type: EXPERIMENTAL
Intervention: 100 mg of 19‐nor‐4‐androstene‐3,17‐dione and 56 mg of 19‐nor‐4‐androstene‐3,17‐diol (156 mg total norsteroid per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (a multivitamin)
Number of subjects: 0
Study: 9893540

Group type: EXPERIMENTAL
Intervention: fentanyl 2 micrograms.kg-1 + ketamine 0.25 mg.kg-1
Number of subjects: 8

Group type: COMPARATOR
Intervention: fentanyl 2 micrograms.kg-1 + placebo
Number of subjects: 8
Study: 8031484

Group type: EXPERIMENTAL
Intervention: Sonicare electronic toothbrush
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B P-35)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual toothbrush (Crest Complete)
Number of subjects: 49
Study: 2525758

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 7972859

Group type: EXPERIMENTAL
Intervention: High-potency neuroleptics treatment for 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no neuroleptic treatment)
Number of subjects: 33
Study: 355071

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 31118098

Group type: EXPERIMENTAL
Intervention: Bovine colostrum-based fortifier
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bovine milk-based fortifier
Number of subjects: 200
Study: 27988288

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Water Immersion (WI)
Number of subjects: 651
Study: 25426617

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg on day 1 for one 3-week cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily)
Number of subjects: 0
Study: 23310947

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m²)
Number of subjects: 25291

Group type: EXPERIMENTAL
Intervention: Underweight patients (BMI < 18.5 kg/m²)
Number of subjects: 25291

Group type: EXPERIMENTAL
Intervention: Men with class 2 and 3 obesity (BMI ≥ 35.0 kg/m²)
Number of subjects: 25291
Study: 21439112

Group type: EXPERIMENTAL
Intervention: Frequent endoscopic cleaning
Number of subjects: 24

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 24
Study: 19458109

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-Xa activity monitoring
Number of subjects: 0
Study: 17394699

Group type: EXPERIMENTAL
Intervention: Finasteride (5alpha-reductase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dutasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E and Selenium
Number of subjects: 0
Study: 15952679

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion in combination with canal injection for local anaesthesia with Mepivacaine 2% and Adrenalin 1/100,000
Number of subjects: 92

Group type: COMPARATOR
Intervention: Local anaesthetic by infiltration of the external canal ear
Number of subjects: 92
Study: 12364308

Group type: EXPERIMENTAL
Intervention: Changes to the order of presenting treatments, improved presentation of information, and redefinition of the non-radical arm.
Number of subjects: 0
Study: 9667262

Group type: EXPERIMENTAL
Intervention: Pegylated-liposomal doxorubicin (20 mg/m2)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Combination of doxorubicin (20 mg/m2), bleomycin (10 mg/m2), and vincristine (1 mg) (ABV)
Number of subjects: 258
Study: 8110579

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg or 30 mg i.m., 6 hourly
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 2530869

Group type: EXPERIMENTAL
Intervention: 10 mg amlodipine administered intravenously
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 18
Study: 1193329

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: cholic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: pretreatment period
Number of subjects: 6
Study: 30894148

Group type: EXPERIMENTAL
Intervention: Humor training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 37
Study: 28392080

Group type: EXPERIMENTAL
Intervention: High-dose loop diuretic strategy (HDLD-strategy)
Number of subjects: 308
Study: 25409951

Group type: EXPERIMENTAL
Intervention: Tapentadol PR (prolonged release)
Number of subjects: 99
Study: 23305630

Group type: EXPERIMENTAL
Intervention: Dietary intervention group (Group B) consuming ≥ 9 servings/day of selected vegetables, fruit and culinary herbs with bone resorbing inhibiting properties.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual diet (Control Group C) with 50 women.
Number of subjects: 100
Study: 21994424

Group type: EXPERIMENTAL
Intervention: MK-0941 10 mg
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: MK-0941 20 mg
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: MK-0941 30 mg
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: MK-0941 40 mg
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: MK-0941 (all doses)
Number of subjects: 587
Study: 18513233

Group type: EXPERIMENTAL
Intervention: 0.5% UVB sunbed sessions (4 sessions of 6 minutes each on days 0, 2, 4, and 7)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1.4% UVB sunbed sessions (4 sessions of 12 minutes each on days 9, 11, 14, and 16)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 16869927

Group type: EXPERIMENTAL
Intervention: Experimental groups with modified CBE programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional groups with standard CBE programme
Number of subjects: 0
Study: 12492802

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micro g kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micro g kg‐1 plus dexamethasone 8 mg
Number of subjects: 120
Study: 11311839

Group type: EXPERIMENTAL
Intervention: Videotapes and written materials under different conditions of presentation
Number of subjects: 624
Study: 9712230

Group type: EXPERIMENTAL
Intervention: Fenfluramine 60 mg orally
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy control subjects (29 subjects) matched for sex and age
Number of subjects: 55
Study: 7986437

Group type: EXPERIMENTAL
Intervention: Caulk Prisma AP.H/Prisma Universal Bond resin composite restorative system
Number of subjects: 60
Study: 2610719

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1089884

Group type: EXPERIMENTAL
Intervention: Early ambulation (mobilized on day six)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Late ambulation (mobilized on day 13)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patients with complications before day six (early ambulation)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Patients with complications before day six (late ambulation)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Early ambulation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Late ambulation
Number of subjects: 129
Study: 30594608

Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 0
Study: 30006653

Group type: EXPERIMENTAL
Intervention: Nasal lavage with saline solution at room temperature (20 °C)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nasal lavage with saline solution at body temperature (37 °C)
Number of subjects: 78
Study: 26825032

Group type: EXPERIMENTAL
Intervention: Maraviroc intensification
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control arm (existing cART regimen)
Number of subjects: 17
Study: 24216624

Group type: EXPERIMENTAL
Intervention: Stevia extracts (stevioside, rebaudioside A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sucrose solution
Number of subjects: 20
Study: 22023518

Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapy before transformation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapy after transformation
Number of subjects: 18

Group type: COMPARATOR
Intervention: No rituximab pre-transformation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rituximab pre-transformation
Number of subjects: 18
Study: 18766955

Group type: EXPERIMENTAL
Intervention: Spironolactone 2 mg/kg/day for 12 weeks
Number of subjects: 24
Study: 17979861

Group type: EXPERIMENTAL
Intervention: Hand-arm bimanual intensive therapy (HABIT); 6 hours per day for 10 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed treatment control group; no specific intervention mentioned.
Number of subjects: 20
Study: 14766494

Group type: EXPERIMENTAL
Intervention: Random practice schedule (intermixed, unsystematic sequence)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Blocked practice schedule (each letter or symbol handwritten 24 times consecutively)
Number of subjects: 172
Study: 11822991

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined nefazodone/CBASP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBASP
Number of subjects: 0
Study: 10102781

Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxyethylamphetamine (MDE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: d-methamphetamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8848903

Group type: EXPERIMENTAL
Intervention: Alfentanil 250 micrograms (n = 18)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg (n = 18)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 51
Study: 1966593

Group type: EXPERIMENTAL
Intervention: glypressin
Number of subjects: 54

Group type: COMPARATOR
Intervention: vasopressin
Number of subjects: 54
Study: 378798

Group type: EXPERIMENTAL
Intervention: Alfason (hydrocortisone‐17 abutyrate)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fluorinated corticoid
Number of subjects: 200
Study: 30328216

Group type: EXPERIMENTAL
Intervention: Traditional AD-protocol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VR-supported AD-protocol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting List (WL) control group
Number of subjects: 54
Study: 28161365

Group type: COMPARATOR
Intervention: Water without licking
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Water with licking
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orange juice alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orange juice with licking
Number of subjects: 24
Study: 26509605

Group type: EXPERIMENTAL
Intervention: 24-week peginterferon/ribavirin treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: 48-week peginterferon/ribavirin treatment
Number of subjects: 152
Study: 24122698

Group type: EXPERIMENTAL
Intervention: Percutaneous electrical neurostimulation (PENS) of dermatome T6 with a 1,200-Kcal diet (group 1)
Number of subjects: 105

Group type: COMPARATOR
Intervention: 1,200-Kcal diet alone (group 2)
Number of subjects: 105

Group type: COMPARATOR
Intervention: PENS of posterior tibial nerve (group 3)
Number of subjects: 105
Study: 21083855

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg per day) for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19299805

Group type: EXPERIMENTAL
Intervention: NS1209 (322 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17410418

Group type: EXPERIMENTAL
Intervention: History of two or more episodes of major depression
Number of subjects: 138

Group type: COMPARATOR
Intervention: History of one episode of major depression
Number of subjects: 138

Group type: COMPARATOR
Intervention: No history of major depression
Number of subjects: 138
Study: 15329598

Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after hepatic/intestinal CYP3A induction by rifampin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after hepatic/intestinal CYP3A inhibition by troleandomycin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OTF (10 microg/kg) after selective intestinal CYP3A inhibition by grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study: 11137181

Group type: EXPERIMENTAL
Intervention: Octreotide (100 mcg/daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 9846791

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride (Decapinol Mouthwash)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (Hibitane Dental)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9747742

Group type: EXPERIMENTAL
Intervention: Single breath test for CO2 (SBT‐CO2)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Lung scintigraphy
Number of subjects: 223
Study: 2067508

Group type: EXPERIMENTAL
Intervention: Mallinckrodt Hi‐Lo‐Evac tube with pharyngeal pack
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mallinckrodt Hi‐Lo‐Evac tube without pharyngeal pack
Number of subjects: 60

Group type: COMPARATOR
Intervention: Portex blue line tube with pharyngeal pack
Number of subjects: 60
Study: 6342836

Group type: EXPERIMENTAL
Intervention: Timolol maleate, 10 mg twice daily
Number of subjects: 1884
Study: 31754161

Group type: EXPERIMENTAL
Intervention: DM with high P2O5 (P1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (P0)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Inorganic P (P3)
Number of subjects: 5
Study: 29166359

Group type: EXPERIMENTAL
Intervention: Transverse specimen extraction
Number of subjects: 165

Group type: COMPARATOR
Intervention: Midline specimen extraction
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis for transverse
Number of subjects: 165

Group type: COMPARATOR
Intervention: Per-protocol analysis for midline
Number of subjects: 165
Study: 27710972

Group type: EXPERIMENTAL
Intervention: Gefitinib beyond progression (n = 21; median duration of continued gefitinib use: 4.2 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stopped gefitinib treatment upon disease progression (n = 35)
Number of subjects: 70
Study: 23981503

Group type: EXPERIMENTAL
Intervention: Contact game
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-contact game
Number of subjects: 23
Study: 22370530

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 74 micrograms
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 micrograms
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study: 21280422

Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Potassium nitrate positive control dentifrice
Number of subjects: 60
Study: 18424480

Group type: EXPERIMENTAL
Intervention: Interferon-beta therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 20
Study: 15881949

Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 45
Study: 12519430

Group type: EXPERIMENTAL
Intervention: 5 microg/kg of filgrastim
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 10 microg/kg of filgrastim
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 5 microg/kg of filgrastim after transplantation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (standard chemotherapy without specified filgrastim dose)
Number of subjects: 131
Study: 10889916

Group type: EXPERIMENTAL
Intervention: Meridol mouthrinse (amine fluoride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 10
Study: 9058693

Group type: EXPERIMENTAL
Intervention: Nebulized ouabain (1 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7939931

Group type: EXPERIMENTAL
Intervention: Iron tablet 1 (60 mg elemental iron)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Iron tablet 2 (60 mg elemental iron)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aqueous Fe(II)-sulphate solution (120 mg elemental iron)
Number of subjects: 18
Study: 3510524

Group type: EXPERIMENTAL
Intervention: Nicardipine (90 mg/day in 3 divided doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day in 3 divided doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25
Study: 29529975

Group type: EXPERIMENTAL
Intervention: Modified stretching exercise program
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 127
Study: 29116494

Group type: EXPERIMENTAL
Intervention: PDT (CMD + PDT)
Number of subjects: 32
Study: 26940585

Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment (HOME) Plus intervention
Number of subjects: 81
Study: 24965551

Group type: EXPERIMENTAL
Intervention: Plain packs of cigarettes
Number of subjects: 128

Group type: COMPARATOR
Intervention: Branded packs of cigarettes
Number of subjects: 128